Related Experiment Video
Updated: Nov 28, 2025
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.4K
CD43 in the malignant flow cytometry laboratory in 2020
1Hematology Laboratory, ICO-Hospital Germans Trias I Pujol, Functional Cytomics- IJC, Universitat Autònoma De Barcelona , Badalona, Spain.
Expert Review of Hematology
|November 30, 2020
Summary
CD43 flow cytometry is crucial for diagnosing B cell malignancies and classifying lymphoproliferative disorders. It aids in quantifying residual disease in chronic lymphocytic leukemia (CLL) and differentiating CD10-positive lymphomas.
Area of Science:
- Hematology
- Immunophenotyping
- Flow Cytometry
Background:
- CD43 is a cell surface marker with established utility in hematologic diagnostics.
- Its application in routine flow cytometry for malignant hematology requires systematic evaluation.
Purpose of the Study:
- To systematically review the applications of CD43 in flow cytometry within malignant hematology.
- To determine the diagnostic and prognostic value of CD43 in various hematologic settings.
Main Methods:
- Systematic literature review of MEDLINE database.
- Search terms included 'CD43' and 'flow cytometry' from 2010 onwards.
- Inclusion criteria focused on studies detailing CD43 use in malignant hematology.
Main Results:
- Twenty-one of 103 retrieved entries met inclusion criteria.
- CD43 is utilized in classifying mature B cell lymphoproliferative disorders.
- It assists in quantifying minimal residual disease in chronic lymphocytic leukemia (CLL) and classifying CD10-positive B cell populations.
Conclusions:
- CD43 plays an increasingly vital role in diagnosing and managing B cell malignancies.
- It is essential for classifying B cell lymphoproliferative disorders and aids in differentiating CD10-positive lymphomas.
- Accurate quantification of CLL residual disease using CD43 is critical for guiding future therapeutic decisions.
